Caption Management’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-120,000
| Closed | -$1.71M | – | 1703 |
|
|
2025
Q4 | $1.71M | Buy |
120,000
+70,000
| +140% | +$688K | 0.01% | 889 |
|
|
2025
Q3 | $394K | Hold |
50,000
| – | – | ﹤0.01% | 1354 |
|
|
2025
Q2 | $287K | Hold |
50,000
| – | – | ﹤0.01% | 1207 |
|
|
2025
Q1 | $408K | Buy |
+50,000
| New | +$463K | ﹤0.01% | 1152 |
|
|
2024
Q3 | – | Sell |
-35,000
| Closed | -$347K | – | 1392 |
|
|
2024
Q2 | $347K | Sell |
35,000
-136,900
| -80% | -$1.41M | 0.01% | 871 |
|
|
2024
Q1 | $2.02M | Buy |
171,900
+16,900
| +11% | +$216K | 0.03% | 528 |
|
|
2023
Q4 | $2.2M | Buy |
155,000
+65,000
| +72% | +$738K | 0.03% | 589 |
|
|
2023
Q3 | $1.09M | Buy |
90,000
+10,000
| +13% | +$129K | 0.02% | 749 |
|
|
2023
Q2 | $1M | Sell |
80,000
-60,000
| -43% | -$712K | 0.02% | 664 |
|
|
2023
Q1 | $1.55M | Buy |
140,000
+40,000
| +40% | +$493K | 0.03% | 516 |
|
|
2022
Q4 | $1.22M | Buy |
+100,000
| New | +$1.13M | 0.02% | 684 |
|
|
2022
Q3 | – | Sell |
-219,100
| Closed | -$2.35M | – | 1618 |
|
|
2022
Q2 | $2.35M | Buy |
+219,100
| New | +$1.8M | 0.03% | 618 |
|
|
2022
Q1 | – | Sell |
-496,400
| Closed | -$5.73M | – | 1623 |
|
|
2021
Q4 | $5.73M | Sell |
496,400
-33,600
| -6% | -$374K | 0.06% | 407 |
|
|
2021
Q3 | $5.06M | Sell |
530,000
-70,700
| -12% | -$723K | 0.06% | 453 |
|
|
2021
Q2 | $5.79M | Sell |
600,700
-114,200
| -16% | -$1.11M | 0.08% | 338 |
|
|
2021
Q1 | $7.06M | Buy |
714,900
+325,900
| +84% | +$5.04M | 0.15% | 169 |
|
|
2020
Q4 | $8.98M | Buy |
389,000
+88,000
| +29% | +$1.8M | 0.2% | 136 |
|
|
2020
Q3 | $4.25M | Buy |
301,000
+156,000
| +108% | +$2.27M | 0.1% | 242 |
|
|
2020
Q2 | $2.19M | Buy |
145,000
+105,000
| +263% | +$1.28M | 0.07% | 360 |
|
|
2020
Q1 | $370K | Buy |
+40,000
| New | +$380K | 0.02% | 598 |
|
|
2019
Q4 | – | Sell |
-20,000
| Closed | -$160K | – | 897 |
|
|
2019
Q3 | $160K | Sell |
20,000
-22,500
| -53% | -$244K | 0.01% | 607 |
|
|
2019
Q2 | $530K | Sell |
42,500
-8,100
| -16% | -$103K | 0.03% | 470 |
|
|
2019
Q1 | $689K | Buy |
+50,600
| New | +$618K | 0.04% | 411 |
|
|
2018
Q2 | – | Sell |
-100,000
| Closed | -$1.5M | – | 403 |
|
|
2018
Q1 | $1.5M | Hold |
100,000
| – | – | 0.21% | 118 |
|
|
2017
Q4 | $1.44M | Buy |
+100,000
| New | +$1.37M | 0.15% | 151 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Caption Management's FOLD Position: Q4 2025 in Review
Caption Management sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 11,100 shares — an estimated $109K sold.
Caption Management first reported a position in FOLD in Q1 2018 and held it in 16 quarters. The position peaked at $4.61M in Q4 2020. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.
- Caption Management reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
- Caption Management sold 11,100 Amicus Therapeutics shares in Q4 2025, an estimated $109K.
- Caption Management first reported a position in Amicus Therapeutics in Q1 2018 and held it in 16 quarters.
- Caption Management's Amicus Therapeutics position peaked at $4.61M in Q4 2020.
- 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.
Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.